The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance(®)), ameliorates glucotoxicity via excret...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Redox Biol
Autors principals: Steven, Sebastian, Oelze, Matthias, Hanf, Alina, Kröller-Schön, Swenja, Kashani, Fatemeh, Roohani, Siyer, Welschof, Philipp, Kopp, Maximilian, Gödtel-Armbrust, Ute, Xia, Ning, Li, Huige, Schulz, Eberhard, Lackner, Karl J., Wojnowski, Leszek, Bottari, Serge P., Wenzel, Philip, Mayoux, Eric, Münzel, Thomas, Daiber, Andreas
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5491464/
https://ncbi.nlm.nih.gov/pubmed/28667906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.redox.2017.06.009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars